Skip to main content
SpringerLink
Log in
Book cover

Replacement of Renal Function by Dialysis pp 953–971Cite as

Endocrine Changes in Chronic Dialysis Patients

  • Chapter

Abstract

There are at least six reasons why endocrine abnormalities may be expected in patients with chronic renal failure (CRF).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Osten B, Kokot F, Klinkmann H: Endokrinologische Störungen bei chronischer Niereninsuffizienz und bei Dauerdialysebehandlung. Teil 1. Renale Hormone-Hypophyse. (Endocrine disorders in chronic renal failure and long-term dialysis treatment. Part I. Renal-hypophyseal hormones.) Dtsch Gesundh-Wesen 37: 2113, 1982

    Google Scholar 

  2. Osten B, Kokot F, Klinkmann H: Endokrinologische Störungen bei chronischer Niereninsuffizienz und bei Dauerdialysebehandlung. Teil 2. Schilddrüse-Nebenschilddrüse-Gastrin-Pancreas Nebenniere-Gonaden. (Endocrine disorders in chronic renal failure and long-term dialysis treatment. Part 2. Thyroid, parathyroid, gastrin, pancreas, adrenal, gonads.) Dtsch Gesundh-Wesen 37: 2196, 1982

    Google Scholar 

  3. Bonomini V, Orsoni G, Stefoni S, Vangelista A: Hormonal changes in uremia Clin Nephrol 11: 275, 1979

    PubMed  CAS  Google Scholar 

  4. Czekalski S: Hormonal abnormalities in chronic uraemia — current nephrological problem. Pol Arch Med Wewn 61: 349, 1979

    PubMed  CAS  Google Scholar 

  5. Kokot F: Endokrinologische Veränderungen bei chronischen Niereninsuffizienz. (Endocrine changes in chronic renal insufficiency.) Z Gesamte Inn Med 35: 34, 1980

    PubMed  Google Scholar 

  6. Lim VS, Kathpalia SC, Henriquez C: Endocrine abnormalities associated with chronic renal failure. Med Clin N Am 62: 1341, 1978

    PubMed  CAS  Google Scholar 

  7. Osten B, Kokot F, Klinkmann H: Endokrinologische Störungen in Hämodialyse, Peritonealdialyse, Membranplasmapheres, (Endocrine Disorders in Hemodialysis, Peritoneal Dialysis and Membrane Plasmapheresis,) edited by Wetzeis E, Colombi A, Dittrich P, Gurland HJ, Kessel N, Klinkmann H, Berlin, Heidelberg, Springer-Verlag, 1986, p 468

    Google Scholar 

  8. Fisher JW: Mechanism of the anemia of chronic renal failure. Nephron 25: 106, 1980

    PubMed  CAS  Google Scholar 

  9. McGonigle RJS, Wallin JD, Shaddusk RK, Fisher JW: Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25: 437, 1984

    PubMed  CAS  Google Scholar 

  10. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175, 1986

    PubMed  CAS  Google Scholar 

  11. Caro J, Brown S, Miller O, Murray TG, Erslev AJ: Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93: 449, 1979

    PubMed  CAS  Google Scholar 

  12. Radtke HW, Frei U, Erbes PM, Schoeppe W, Koch KM: Improving anemia by hemodialysis: Effect on serum erythropoietin. Kidney Int 17: 328, 1980

    Google Scholar 

  13. Mason C, Thomas TH: A model for erythropoiesis in experimental chronic renal failure. Br J Haemat 58: 729, 1984

    CAS  Google Scholar 

  14. Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M: Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients. Nephron 39: 26, 1985

    PubMed  CAS  Google Scholar 

  15. Shalhoub RJ, Rajan UR, Kim VV, Goldwasser V, Kark JA, Antoniou LD: Erythrocytosis in patients on long term hemodialysis. Ann Intern Med 97: 686, 1982

    PubMed  CAS  Google Scholar 

  16. Thompson BJ, Jenkins DAS, Allan PL, Elton RA, Winney RJ: Acquired cystic disease of the kidney in patients with end-stage chronic renal failure. Nephrol Dial Transplant 1: 38, 1986

    Google Scholar 

  17. Anagnostou A, Kurtzman NA: Hematological consequences of renal failure in The Kidney, edited by Brenner BM, Rector FC, Philadelphia, Saunders WB Co, 1986, p 1631

    Google Scholar 

  18. Brown S, Caro J, Erslev AJ, Murray TG: Spontaneous increase in erythropoietin and hematocrit value associated with transistent liver enzyme abnormalities in an anephric patient undergoing hemodialysis. Am J Med 68: 280, 1980

    PubMed  CAS  Google Scholar 

  19. Simon P: Improvement of anemia in hemodialysed patients after viral and toxic hepatic cytolysis. Br Med J 280: 892, 1980

    PubMed  CAS  Google Scholar 

  20. Meytes D, Bogin E, Andrew MA, Dukes PP, Massry SG: Effect of parathyroid hormone of erythropoiesis. J Clin Invest 67: 1263, 1981

    PubMed  CAS  Google Scholar 

  21. Podjany E: Is anemia of chronic renal failure related to secondary hyperparathyroidism? Arch Intern Med 141: 453, 1981

    Google Scholar 

  22. Wallner SF, Vautrin RM: Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J Lab Clin Med 97: 170, 1981

    PubMed  CAS  Google Scholar 

  23. Zappacosta AR, Caro J, Erslev AI: Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis: the role of erythropoietin. Am J Med 75: 53, 1982

    Google Scholar 

  24. Dagher FJ, Ramos E, Erslev AJ, Alongi SV, Karmi SA, Caro J: Are the native kidneys responsible for erythrocytosis in renal allografts? Transplantation 28: 296, 1979

    Google Scholar 

  25. Thevenod F, Radtke HW, Grützmacher P, Vincent E, Koch KM, Schoeppe W, Fassbinder W: Deficient feedback regulation of erythrocytosis in kidney transplant patients with polycythemia. Kidney Int 24: 227, 1983

    PubMed  CAS  Google Scholar 

  26. Kawashima H, Kurokawa K: Metabolism and sites of action of vitamin D in the kidney. Kidney Int 29: 98, 1986

    PubMed  CAS  Google Scholar 

  27. Fräser DR: Regulation of the metabolism of vitamin D. Physiol Rev 60: 551, 1980

    PubMed  Google Scholar 

  28. Jongen MJM, van der Vijgh WJF, Lips P, Netelenbos JC: Measurements of vitamin D metabolites in anephric subjects. Nephron 36: 230, 1984

    PubMed  CAS  Google Scholar 

  29. Rickers H, Christiansen C, Christensen P, Christensen M, R0dbro P: Serum concentrations of vitamin D metabolites in different degrees of impaired renal function. Estimation of renal and extrarenal secretion rate of 24, 25-dihydroxyvitamin D. Nephron 39: 267, 1985

    PubMed  CAS  Google Scholar 

  30. Shany S, Rapoport J, Goligorsky M, Yankowitz N, Zuili I, Chaimovitz C: Losses of 1-25- and 24, 25-dihydroxycholecalciferol in the peritoneal fluid of patients treated by continuous ambulatory peritoneal dialysis. Nephron 36: 111, 1984

    PubMed  CAS  Google Scholar 

  31. Shany S, Rapoport J, Zuili I, Yankowitz N, Chaimovitz C: Enhancement of 24, 25-dihydroxyvitamin D levels in patients treated with continuous ambulatory peritoneal dialysis. Nephron 42: 141, 1986

    PubMed  CAS  Google Scholar 

  32. Aloni J, Shany S, Chaimovitz C: Loss of 25-hydroxyvitamin D in peritoneal fluid: possible mechanisms for bone disease in patients treated with chronic ambulatory peritoneal dialysis. Miner Eelectrolyte Metab 9: 82, 1983

    CAS  Google Scholar 

  33. Merke J, Ritz E, Boland R: Are recent findings on 1, 25- dihydroxycholecalciferol metabolism relevant for the pathogenesis of uremia? Nephron 42: 277, 1986

    PubMed  CAS  Google Scholar 

  34. Massry SG: The toxic effect of parathyroid hormone in uremia. Semin Nephrol 3: 306, 1984

    Google Scholar 

  35. Lebel M, Grose JH: Abnormal renal prostaglandin production during the evolution of chronic nephropathy. Am J Nephrol 6: 96, 1986

    PubMed  CAS  Google Scholar 

  36. Papanicolaou N, Mountokalakis T, Pallasides P, Palis M, Bariety J, Papavassillou J, Merikas G, Miliez P: Urinary prostaglandin in kidney disease. Prostaglandins Med 3: 47, 1979

    PubMed  CAS  Google Scholar 

  37. Schneider M, Rathaus M, Shapiro J, Bernheim J: Urinary prostaglandins E2 and F2α in chronic renal failure. Nephron 40: 152, 1985

    PubMed  CAS  Google Scholar 

  38. Borges MF, Kjellstrand CM: The effect of prostaglandins inhibition on the clinical course of chronic hemodialysis. Nephron 42: 122, 1986

    Google Scholar 

  39. Blum M, Bauminger S, Algneti A, Kisch E, Ayalen D, Aviram A: Urinary prostaglandin E in chronic renal disease. Clin Nephrol 15: 87, 1981

    PubMed  CAS  Google Scholar 

  40. Kimberly RP, Gill JR, Bowden RE, Keiser HR, Plötz PH: Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med 89: 336, 1978

    PubMed  CAS  Google Scholar 

  41. McGiff JC, Crowshow K, Teroagno NA, Lonigro AJ, Svand JC, Williamson MA, Lee JB, Ng KKE: Prostaglandin-like substances appearing in canine renal venous blood during renal ischemia. Their partial characterization by pharmacologic and chromatographic procedures. Circ Res 27: 765, 1970

    PubMed  CAS  Google Scholar 

  42. Berg KJ: Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency. Eur J Clin Pharmacol 11: 111, 1977

    PubMed  CAS  Google Scholar 

  43. Schlondorff D, Ardaillou R: Prostaglandins and other arachidonic acid metabolites in the kidney. Kidney Int 29:108, 1986

    PubMed  CAS  Google Scholar 

  44. Gryglewski RJ, Korbut R, Ocetkiewicz A: Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature 273: 765, 1978

    PubMed  CAS  Google Scholar 

  45. Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS: Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 296: 769, 1977

    PubMed  CAS  Google Scholar 

  46. Batlle DC, von Riotte A, Lang G: Delayed hypotensive response to dialysis in hypertensive patients with end-stage renal disease. Am J Nephrol 6: 14, 1986

    PubMed  CAS  Google Scholar 

  47. Kuska J, Kokot F, Libera T, Sledzinski Z: The influence of upright position and sodium restriction in the diet on plasma renin activity (PRA) and aldosteronemia in patients with chronic nephritis. Mater Med Pol 9: 312, 1977

    PubMed  CAS  Google Scholar 

  48. Kuska J, Kokot F, Panusz J: Regulation and significance of renin-angiotensin-aldosterone axis in patients with chronic nephritis. Mater Med Pol 10: 54, 1978

    PubMed  CAS  Google Scholar 

  49. Kokot F, Kuska J: Plasma renin activity in patients with acute and chronic renal insufficiency treated by hemodialysis. Proc Eur Dial Transplant Assoc 8: 542, 1971

    Google Scholar 

  50. Kornerup HJ, Schmitz O, Danielsen H, Pedersen EB, Giese J: Significance of the renin-angiotensin system for blood pressure regulation in end-stage renal disease. Contrib Nephrol 41: 123, 1984

    PubMed  CAS  Google Scholar 

  51. Weidmann P, Maxwell M: The renin-angiotensin-aldosterone system in terminal renal failure. Kidney Int 8 (Suppl 5): 219, 1975

    Google Scholar 

  52. Warren DJ, Ferris TF: Renin secretion in renal hypertension. Lancet 1: 159, 1970

    PubMed  CAS  Google Scholar 

  53. d’Amore TF, Wauters JP, Waeber B, Brunner HR: Salt subtraction in patients on maintenance hemodialysis. Efficacy and limitations. Am J Nephrol 5: 275, 1985

    Google Scholar 

  54. Naik RB, Mathias CJ, Reid JL, Warren DJ: Effect of haemodialysis on the control of the circulation in patients with chronic renal failure. Am J Nephrol 5: 96, 1985

    PubMed  CAS  Google Scholar 

  55. Nielsen AH, Knudsen F, Kristensen SD: Serum angiotensin-converting enzyme increases during hemodialysis. Evidence for injury of the pulmonary vascular endothelium. Nephron 40: 100, 1985

    PubMed  CAS  Google Scholar 

  56. Silverstein E, Brunswick J, Rao TKS, Friedland J: Increased serum angiotensin-converting enzyme in chronic renal disease. Nephron 37: 206, 1984

    PubMed  CAS  Google Scholar 

  57. Rumpf KW, Brat A, Armstrong V, Scheler F: Increased serum angiotensin-converting enzyme in end-stage renal disease. Nephron 40: 248, 1985

    PubMed  CAS  Google Scholar 

  58. Le Treut A, Chevet D, Guenet L, Leray G, Afiouni N, Le Pogamp P, Le Gall JY: Serum angiotensin-converting enzyme levels in patients with chronic renal failure. Path Biol (Paris) 31: 182, 1983

    Google Scholar 

  59. Scicli AG, Carretero OA: Renal kallikrein-kinin system. Kidney Int 29: 120, 1986

    PubMed  CAS  Google Scholar 

  60. Funaki N, Kuroda M, Sudo J, Takeda R: Urinary prostaglandin and kallikrein in the course of acute renal failure. Pros Leuk Med 9: 387, 1982

    CAS  Google Scholar 

  61. Mayfield RK, Margolius HS: Renal kallikrein-kinin system. Am J Nephrol 3: 145, 1983

    PubMed  CAS  Google Scholar 

  62. Mitas JA, Lavy SB, Holle R, Frigon RP, Stone RA: Urinary kallikrein activity in the hypertension of renal parenchymal disease. N Engl J Med 299: 162, 1978

    PubMed  CAS  Google Scholar 

  63. Brouhard BM, Cunningham RJ, Berger M, Petrusick TW, Travis LB: Urinary kallikrein excretion in renal transplant patients. Clin Nephrol 17: 241, 1982

    PubMed  CAS  Google Scholar 

  64. Koolen MJ, van Brummelen P, Paul LC, Daha MR, van Es LA: Excretion of urokallikrein in renal transplant patients. Transplantation 37: 471, 1984

    PubMed  CAS  Google Scholar 

  65. Grzeszczak W, Kokot F, Dulawa J: Effects of naloxone administration on endocrine abnormalities in chronic renal failure. Am J Nephrol 7: 93, 1987

    PubMed  CAS  Google Scholar 

  66. Kuska J, Kokot F, Sledzinski Z: Secretion of growth hormone after L-dopa stimulation in patients with renal failure treated with dialysis. Acta Med Pol 20: 217, 1979

    PubMed  CAS  Google Scholar 

  67. Ijaya K: Pattern of growth hormone response to insulin, arginine and haemodialysis in uraemic children. Eur J Pediatr 131: 185, 1979

    Google Scholar 

  68. Kokot F, Kuska J: Das Verhalten des Wachstumshormons nach Insulin-Stimulierung bei chronischer Niereninsuffizienz. (Behavior of growth hormone following insulin stimulation in chronic renal failure.) Z Gesamte Inn Med 27: 207, 1972

    PubMed  CAS  Google Scholar 

  69. Davidson MB, Fisher MB, Dabir-Vaziri N, Schaffer M: Effect of protein intake and dialysis on the abnormal growth hormone, glucose and insulin homeostasis in uremia. Metabolism 25: 455, 1976

    PubMed  CAS  Google Scholar 

  70. Bundschu HD: Endokrine Störungen bei Niereninsuffizienz. (Endocrine disorders in renal insufficiency.) In: Blutreinigungsverfahren (Methods of Blood Purification), edited by Franz HE, Stuttgart, New York, G. Thieme Verlag, 1981, p 222

    Google Scholar 

  71. Saenger P, Wiedemann E, Schwartz E, Korth-Schutz S, Levy JE, Ribbio RR, Rubin A, Stenzel KH, New MI: Somatomedin and growth after renal transplantation. Pediatr Res 8:164, 1974

    Google Scholar 

  72. Pimstone BL, Le Roith D, Epstein S, Kronheim S: Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease. J Clin Endocrinol Metab 41: 392, 1975

    PubMed  CAS  Google Scholar 

  73. Spanos E, Barrett D, Maclntyre I, Pike JW, Safilian EE, Haussler MR: Effect of growth hormone on vitamin D metabolism. Nature 273: 246, 1978

    PubMed  CAS  Google Scholar 

  74. Eshildsen PC, S0rensen OH, Bishop JE, Norman AW: Acromegaly and vitamin D metabolism: effect of bromocriptine treatment. J Clin Endocrinol Metab 49: 484, 1979

    Google Scholar 

  75. Schüllerova M, Marek J, Schreiberova O, Tomasek R, Josifko M: Somatomedin in patients with chronic renal insufficiency. Čas Lék Cěs 116: 519, 1977

    Google Scholar 

  76. Philips LS, Kopple JD: Circulating somatomedin activity and sulfate levels in adults with normal and impaired kidney function. Metabolism 30: 1091, 1981

    Google Scholar 

  77. Schriffrin A, Guyda H, Robitaille P, Posner B: Increased plasma somatomedin reactivity in chronic renal failure as determined by acid gel filtration and radioreceptor assay. J Clin Endocrinol Metab 46: 511, 1978

    Google Scholar 

  78. Bereu BB, Corden BJ, Schulman BJ, Rizzo WB, Reed GR: Circulating somatomedin-C levels in nephropathic cystinosis. Isr J Med Sci 20: 236, 1984

    Google Scholar 

  79. Phillips LS, Vassilopoulou: Sellin R: Somatomedins. N Engl J Med 302, 371, 438, 1980

    Google Scholar 

  80. Goldberg AC, Trivedi B, Delmez JA, Harter HR, Daughaday WH: Uraemia reduces serum insulin like growth factor I, increases insulinlike growth factor II, and modifies their serum protein binding. J Clin Endocrinol Metab 55: 1040, 1982

    PubMed  CAS  Google Scholar 

  81. French CB, Genel M: Pathophysiology of growth failure in chronic renal insufficiency. Kidney Int 29 (Suppl 19): S59, 1986

    Google Scholar 

  82. Philips LS, Fusco AC, Unterman TG, Del Greco F: Somatomedin inhibotor in uremia. J Clin Endocrinol Metab 59: 764, 1984

    Google Scholar 

  83. Lim VS, Kathpalia SC, Frohman LA: Hyperprolactinemia and impaired pituitary response to suppression and stimulation in chronic renal failure: reversal after transplantation. J Clin Endocrinol Metab 48: 101, 1979

    PubMed  CAS  Google Scholar 

  84. Ijaaiya K, Roth B, Schwenk A: Serum prolactin level in renal insufficiency in children. Acta Paediatr Scand 69: 299, 1980

    Google Scholar 

  85. Grzeszczak W, Kokot F, Dulawa J: Influence of naloxone on prolactin secretion in patients with acute and chronic renal failure. Clin Nephrol 21: 47, 1984

    PubMed  CAS  Google Scholar 

  86. Sievertsen GD, Lim VS, Nakawatase C, Frohman LA: Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab 50: 846, 1980

    PubMed  CAS  Google Scholar 

  87. Preces R, Horcajada C, Lopez-Novoa JM, Frutos MA, Casado S, Hernando L: Hyperprolactinemia in chronic renal failure. Impaired responsiveness to stimulation and suppression. Normalization after transplantation. Nephron 28: 11, 1981

    Google Scholar 

  88. Grzeszczak W, Kokot F, Dulawa J: Naloxone effect on the secretion of lutropin (LH) folitropin (FSH) prolactin and testosterone in patients with chronic renal failure. Pol Arch Med Wewn 73: 278, 1985

    PubMed  CAS  Google Scholar 

  89. Bauer AGC, Wilson JHP, Lamberts SWJ: The kidney is the main site of prolactin elimination in patients with liver disease. J Clin Endocrinol Metab 51: 70, 1980

    PubMed  CAS  Google Scholar 

  90. Kokot F, Grzeszczak W, Dulawa J: Besteht eine Beziehung zwischen der Parathormon- und Prolactinsekretion bei Kranken mit akutem und chronischem Nierenversagen? (Is there a relation between parathormone and prolactin secretion in patients with acute and chronic renal failure?) Z Gesamte Inn Med 39: 40, 1984

    PubMed  CAS  Google Scholar 

  91. Spanos E, Coston KW, Ewans LMS, Galante LS, McAuley SJ, Maclntyre I: Effect of prolactin on vitamin D metabolism. Mol Cell Endocrinol 5: 163, 1976

    PubMed  CAS  Google Scholar 

  92. Kokot F: Endokrinologische Veränderungen bei der chronischen Niereninsuffizienz. (Endocrine changes in chronic renal insufficiency.) Z Gesamte Inn Med 34: 743, 1979

    Google Scholar 

  93. Barbour GL, Sevier BR: Adrenal responsiveness in chronic hemodialysis. N Engl J Med 290: 1258, 1974

    PubMed  CAS  Google Scholar 

  94. McDonald WJ, Golper TA, Mass RD, Kendall JW, Porter GA, Girard DE, Fischer MD: Adrenocorticotropin-Cortisol axis abnormalities in hemodialysis patients. J Clin Endocrinol Metab 48: 92, 1979

    PubMed  CAS  Google Scholar 

  95. Akmad M, Manziar AD: Simplified assessment of pituitary adrenal axis in a stable group of chronic hemodialysis patients. Trans Am Soc Artif Intern Organs 23: 703, 1977

    Google Scholar 

  96. Bacon GE, Kenny FM, Murdaugh HV, Richards C: Prolonged serum halflife of Cortisol in renal failure. J Hopkins Med J 132: 127, 1973

    CAS  Google Scholar 

  97. Feldman H, Singer I: Endocrinology and metabolism in uremia and dialysis: a clinical review. Medicine 54: 345, 1974

    Google Scholar 

  98. Gilkes JJH, Eady RAJ, Rees LH, Munro DD, Moorhead JF: Plasma immunoreactive melantrophic hormones in patients on maintenance haemodialysis. Br Med J 1: 656, 1975

    Google Scholar 

  99. Knopp E, Staudinger E, v Dittrich P: Das Verhalten des freien Plasmakortisols während extrakorporaler Hämodialyse. (Behavior of free plasma Cortisol during extracorporeal hemodialysis.) Klin Wochenschr 48: 1243, 1970

    Google Scholar 

  100. Ramirez G, Etheridge P, Meikle W, Jubiz W: Evaluation of the pituitary adrenal axis in patients with chronic renal failure. Clin Res 26: 148 (Abstract), 1978

    Google Scholar 

  101. Rosman PM, Benn R, Kay M, Rito J, Wallace EZ: Cortisol binding in uremic plasma. I. Absence of abnormal Cortisol binding to corticosteroid-binding globulin. Nephron 37: 160, 1984

    PubMed  CAS  Google Scholar 

  102. Bindeballe W, Drenkhahn E, Jüsgen W, Lahrtz H, Heybold K, Niedermayer W, Schemmel K: Der Einfluss der Hämodialyse auf den Hormonstatus bei terminaler Niereninsuffizienz. (The influence of hemodialysis on the hormone status in terminal renal failure.) Dtsch Med Wochenschr 98: 661, 1973

    PubMed  CAS  Google Scholar 

  103. Kolbe K: Untersuchungen zur Kortisolproduktion bei Patienten mit terminaler Niereninsuffizienz während der Hämodialysebehandlung. (Investigation of Cortisol production in patients with terminal renal failure undergoing hemodialysis treatment.) Dissertation, Aachen, 1979

    Google Scholar 

  104. Kapstein EM, Feinstein EJ, Nicoloff JT, Massry SG: Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure. J Clin Endocrinol Metab 57: 181, 1983

    Google Scholar 

  105. Kaptein EM, Feinstein EI, Massry SG: Thyroid hormone metabolism in renal diseases. Contrib Nephrol 33: 122, 1982

    PubMed  CAS  Google Scholar 

  106. Giordano C, DeSanto NG, Carella C, Capodicasa G, Amato G, Nuzzi F, Mioli V, Bazzato G, De Simone V, Tarchini A, Landini A, Coli U, Bordoni M, Mottola G, Capuano F: Thyroid status and nephron loss — a study in patient with chronic renal failure, end-stage renal disease and/or hemodialysis. Int J Artif Organs 7: 119, 1984

    PubMed  CAS  Google Scholar 

  107. Beckers C, van Ypersele, de Strihou C, Coche E, Troch R, Malvaux P: Iodine metabolism in severe renal insufficiency. J Clin Endocrinol Metab 29: 293, 1969

    PubMed  CAS  Google Scholar 

  108. Kontras DA, Marketos SG, Rigopoulos GA, Melamos B: Iodine metabolism in chronic renal insufficiency. Nephron 9: 55, 1972

    Google Scholar 

  109. Lim VS, Fang VS, Katz AJ, Refetoff S: Thyroid dysfunction in chronic renal failure: a study of the pituitary thyroid axis and peripheral turnover kinetics of thyroxine and triiodothyronine. J Clin Invest 60: 522, 1977

    PubMed  CAS  Google Scholar 

  110. Kalk WJ, Morley JE, Gold GH, Meyers A: Thyroid function tests in patients on regular hemodialysis. Nephron 25: 173, 1980

    PubMed  CAS  Google Scholar 

  111. Beckett GJ, Henderson CJ, Elwes R, Seth J, Lambie AT: Thyroid status in patients with chronic renal failure. Clin Nephrol 19: 172, 1983

    PubMed  CAS  Google Scholar 

  112. Inaba M, Nishizawa Y, Nishitani H, Miki T, Onishi Y, Mizutarii Y, Yamakawa M: Concentrations of thyroxine-binding globulin in sera and peritoneal dialysates in patients on chronic peritoneal ambulatory dialysis. Nephron 42: 58, 1986

    PubMed  CAS  Google Scholar 

  113. Sennesal JJ, Verbeelen DL, Jonckeer MH: Thyroid dysfunction in patients on regular hemodialysis: Evaluation of the stable intrathyroidal iodine pool, incidence of goiter and free thyroid hormone concentration. Nephron 41: 141, 1985

    Google Scholar 

  114. Thysen B, Gatz M, Freeman R, Alpert BE, Charytan C: Serum thyroid hormone levels in patients on continuous peritoneal dialysis and regular hemodialysis. Nephron 33:49, 1983

    PubMed  CAS  Google Scholar 

  115. Ciardella F, Morelli E, Caprioli R, Casto G, Christu C, Rampa P, Petronio MG, Carbone C, Mantovanell A, Mazzotta L, Barsotti G: Restoration of thyroid secretion in uremic patients following a low protein, low phosphorus diet, supplemented with essential amino acids and keto analogues. Contrib Nephrol 53: 51, 1986

    PubMed  CAS  Google Scholar 

  116. Czekalski S, Malczewska B, Sobieszczyk S, Kozak W, Eder M, Gryczyńska M, Bczyk K, Kosowicz J: Comparison of some circulating pituitary thyroid and gonadal hormone levels in nondialyzed and dialyzed males with chronic renal failure. Dial Transplant 10: 438, 1981

    Google Scholar 

  117. Hegedüs L, Andersen JR, Poulsen LR, Perrild H, Holm B, Gundtoft E, Hansen JM: Thyroid gland volume and serum concentrations of thyroid hormones in chronic renal failure. Nephron 40: 171, 1985

    PubMed  Google Scholar 

  118. Czernichow P, Danzet MC, Brover M, Rappaport R: Abnormal TSH, PRL and GH in chronic uremia. J Clin Endocrinol Metab 43:630, 1976

    PubMed  CAS  Google Scholar 

  119. Semple CG, Beastall GH, Henderson JS, Thomsom MA, Kennedy AC: Thyroid function and continuous ambulatoryperitoneal dialysis. Nephron 32: 249, 1982

    PubMed  CAS  Google Scholar 

  120. Davis FB, Spector DA, Davis PH, Hirsch BR, Walshe JJ, Yoshida K: Comparison of pituitary-thyroid function in patients with end-stage renal disease and in age- and sex matched controls. Kidney Int 21: 362, 1982

    PubMed  CAS  Google Scholar 

  121. Vaziri ND, Gvinup C, Martin D, Seltzer J: Thyroid function in chronic renal failure after successful renal transplantation. Clin Nephrol 15: 131, 1981

    CAS  Google Scholar 

  122. DeSanto NG, Carella C, Fine RN, Lenmann E, Fine S, Amato G, Capodicasa G, Nuzzi F, Capasso G, Simone V, Lama G, Scoppa F: Thyroid function in uremic children — studies at various stages of nephron loss and during treatment with hemodialysis and/or CAPD. Contrib Nephrol 49: 56, 1985

    PubMed  CAS  Google Scholar 

  123. Foley RJ, Hamner RW: Hyperthyroidism in end-stage renal disease. Am J Nephrol 5: 292, 1985

    PubMed  CAS  Google Scholar 

  124. Massry SG, Goldstein DA, Procci WR, Kletzky OA: On the pathogenesis of sexual dysfunction of the uraemic male. Proc Eur Dial Transplant Assoc 17: 139, 1980

    PubMed  CAS  Google Scholar 

  125. Czekalski S, Malczewska B, Sowinski J, Sobieszczak S, Kozak W, Eder M, B§czyk K: Serum concentration of pituitary, thryoid and gonadal hormone in nondialyzed and dialyzed males with chronic renal failure. Proc Eur Dial Transplant Assoc 15: 599, 1978

    PubMed  CAS  Google Scholar 

  126. Distiller LA, Morely JE, Sagel J, Pokroy M, Rabkin R: Pituitary gonadal function in chronic renal failure. The effect of luteinizing releasing hormone and the influence of dialysis. Metabolism 24: 711, 1975

    PubMed  CAS  Google Scholar 

  127. Holdsworth S, Atkins RC, Kretser DM de: The pituitary-testicular axis in men with chronic renal failure. N Engl J Med 296, 1245, 1977

    PubMed  CAS  Google Scholar 

  128. Krolner B: Serum levels of testosterone and luteinizing hormone in patients with chronic renal disease. Acta Med Scand 205: 623, 1979

    PubMed  CAS  Google Scholar 

  129. Lim VS, Fang WR: Gonadal dysfunction in uremic men. Am J Med 58: 655, 1975

    PubMed  CAS  Google Scholar 

  130. Swamy AP, Woolf PD, Cestero RVM: Hypothalamic-pituitary-ovarian axis in uremic women. J Lab Clin Med 93: 1066, 1979

    PubMed  CAS  Google Scholar 

  131. Mastrogiacomo I, De Besi L, Zucchetta P, Serafini E, Gasparotto ML, Marchini P, Pisani E, Dean P, Chini M: Effect of hyperprolactinemia and age on the hypogonadism of uremic men on hemodialysis. Arch Androl 12: 235, 1984

    PubMed  CAS  Google Scholar 

  132. Joven J, Villabona C, Rubi es-Prat J, Espinel E, Galard R: Hormonal profile and serum zinc levels in uraemic men with gonadal dysfunction undergoing haemodialysis. Clin Chim Acta 148: 239, 1985

    PubMed  CAS  Google Scholar 

  133. Van Coevorden A, Stolear J, Dhaene M, Van Herweghem JL, Mockel J: Effect of chronic oral testosterone undecannoate administration the pituitary-testicular axis of hemodialyzed male patients. Clin Nephrol 26: 48, 1986

    PubMed  Google Scholar 

  134. Grzeszczak W, Kokot F, Wi)cek A: Importance of opioid receptors in the pathogenesis of endocrine abnormalities in chronic renal failure. Contrib Nephrol 78: 261, 1987

    Google Scholar 

  135. Barsotli G, Ciardella F, Morelli E, Fioretti P, Melis G, Paoletti A, Niosi F, Caprioli R, Fosso A, Carbone C, Giovanetti S: Restoration of blood levels of testosterone in male uremics following a low protein diet supplemented with essential amino acids and ketoanalogues. Contrib Nephrol 49: 63, 1985

    Google Scholar 

  136. Lim VS, Henriguez C, Sievertsen G, Frohman LA: Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation. Ann Intern Med 93: 21, 1980

    PubMed  CAS  Google Scholar 

  137. Massry SG: Current status of the role of parathyroid hormone in uremic toxicity. Contrib Nephrol 49: 1, 1985

    PubMed  CAS  Google Scholar 

  138. Ermolenko UM, Kukhtewitch AV, Dedov II, Bunatian AF, Melnichenko GA, Gitel EP: Parlodel treatment of uremic hypogonadism in men. Nephron 42: 19, 1986

    PubMed  CAS  Google Scholar 

  139. Ardaillou R, Benmansour M, Roudeau E, Caillens H: Metabolism and secretion of antidiuretic hormone in patients with renal failure, cardiac insufficiency, and liver insufficiency. Adv Nephrol 13: 35, 1984

    CAS  Google Scholar 

  140. Ben Mausour M, Rainfray M, Paillard F, Ardaillou R: Metabolic clearance rate in immunoreactive vasopressin in man. Eur J Clin Invest 12: 475, 1982

    Google Scholar 

  141. Munoz EP, Easterling RE, Malvin RL: The effect of plasma calcium on plasma ADH level in anephric patients. Nephron 16: 49, 1976

    Google Scholar 

  142. Horky K, Sramkova J, Lachmanova J, Tomasek R, Dvorakova J: Plasma concentration of ADH in patients with chronic renal insufficiency on maintenance dialysis. Horm Metab Res 11: 241, 1979

    PubMed  CAS  Google Scholar 

  143. Vaziri ND, Skowsky R, Warner A: Effect of isomolal volume reduction during hemofiltration on plasma ADH in patients with chronic renal failure. Int J Artif Organs 3: 322, 1980

    PubMed  CAS  Google Scholar 

  144. Vaziri ND, Skowsky R, Saiki J, Warner A: Hemodialysis studies of antidiuretic hormone. J Dial 4: 185, 1980

    PubMed  CAS  Google Scholar 

  145. Shimamoto R, Watari J, Miyahara M: A study of plasma vasopressin in patients undergoing chronic hemodialysis. J Clin Endocrinol Metab 45: 714, 1977

    PubMed  CAS  Google Scholar 

  146. Caillenns M, Pruszczyriski W, Meyrier A, Ang KS, Rousselet F, Ardaillou R: Relationship between change in volemia at constant osmolality and plasma antidiuretic hormone. Miner Electrolyte Metab 4: 161, 1980

    Google Scholar 

  147. Jawadi MH, Ho LS, Dipette D, Ross DL: Regulation of plasma arginine vasopressin in patients with chronic renal failure maintained on hemodialysis. Am J Nephrol 6:175, 1986

    PubMed  CAS  Google Scholar 

  148. Iitake K, Kimura T, Matsui K, Ota K, Shoji M, Inoue M, Yoshinaga K: Effect of haemodialysis on plasma ADH levels, plasma renin activity and plasma aldosterone levels in patients with end-stage renal disease. Acta Endocrinol (Kbh) 110: 207, 1985

    PubMed  CAS  Google Scholar 

  149. Fasanella dAmore T, Wauter JP, Weber B, Nussberger J, Brunner HR: Response of plasma vasopressin to change in extracellular volume and/or plasma osmolality in patients on maintenance hemodialysis. Clin Nephrol 23: 299, 1985

    CAS  Google Scholar 

  150. Grzeszczak W, Kokot F, Dulawa J, Kuska J: Effect of naloxone on vasopressin secretion in patients with acute and chronic renal failure. Pol Arch Med Wewn 74: 176, 1985

    PubMed  CAS  Google Scholar 

  151. Vaziri ND, Skousky R, Warner A: Effect of isoosmolar volume reduction during hemofiltration on plasma antidiuretic hormone in patients with chronic renal failure. Int J Artif Organs 3: 322, 1980

    PubMed  CAS  Google Scholar 

  152. Hammer M, Olgaard K, Madsen S: The inability of angiotensin II infusion to raise plasma vasopressin levels in haemodialysis patients. Acta Endocrinol 95: 422, 1980

    PubMed  CAS  Google Scholar 

  153. Ben Mansour M, Caillens H, Ardaillou R: The effect of inhibition of angiotensin II synthesis on the response of plasma antidiuretic hormone to the osmotic and volume dependent stimuli in uremic patients. Nephrologie 1: 109, 1980

    CAS  Google Scholar 

  154. Hammer M, Ladefoged J, Madsen S, Olgaard K, Tuegeaard E: Calcium-stimulated vasopressin secretion in uremic patients: an effect mediated via parathyroid hormone. J Clin Endocrinol Metab 51: 1070, 1980

    Google Scholar 

  155. Nieszporek T, Grzeszczak W, Kokot F, Szczechowska E, Wiscek A: Renin-angiotensin aldosterone system and vasopressin secretion in renal transplant recipients treated by cyclosporin A or azathioprine with prednisone. Pol Arch Med Wewn 78: 261, 1987

    PubMed  CAS  Google Scholar 

  156. Fräser DR, Kodicek E: Unique biosynthesis by kidney of a biologically active vitamin D metabolite. Nature 228: 764, 1970

    PubMed  Google Scholar 

  157. Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82: 4270, 1985

    PubMed  CAS  Google Scholar 

  158. Llach F, Massry SG: On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 61: 601, 1985

    PubMed  CAS  Google Scholar 

  159. Massry SG, Tuma S, Dua S, Goldstein DA: Reversal of skeletal resistance to parathyroid hormone in uremia by vitamin D metabolites. J Lab Clin Med 94: 152, 1979

    PubMed  CAS  Google Scholar 

  160. Rutherford WE, Bordier P, Marie P, Hruska K, Harter H, Greenwalt A, Blondin J, Haddad J, Bricker N, Slatopolsky E: Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J Clin Invest 60: 332, 1977

    PubMed  CAS  Google Scholar 

  161. Slatopolsky ES, Caglar S, Gradowska L, Canterbury J, Reiss E, Bricker NS: On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using ’proportional reduction’ of dietary phosphorus intake. Kidney Int 2: 147, 1972

    PubMed  CAS  Google Scholar 

  162. Brown EM, Wilkinson RE, Eastman RC, Pallotta J, Marynick SP: Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 54: 172, 1982

    PubMed  CAS  Google Scholar 

  163. Freitag J, Marlin KJ, Hruska KA, Anderson C, Conrades M, Landenson J, Klahr S, Slatopolsky E: Impaired parathyroid hormone metabolism in patients with chronic renal failure. N Engl J Med 298: 29, 1978

    PubMed  CAS  Google Scholar 

  164. Lopez-Hilker S, Galceran T, Chan YL, Rapp N, Martin KJ, Slatopolsky E: Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 78: 1097, 1986

    PubMed  CAS  Google Scholar 

  165. Grzeszczak W, Kokot F, Dulawa J: Einfluss von Naloxone auf die Parathormon- und Calcitoninsekretion bei Kranken mit akuter und chronischer Niereninssuffizienz. (Effect of naloxone on parathormone and calcitonin secretion in patients with acute and chronic renal failure.) Z Klin Med 41: 435, 1986

    Google Scholar 

  166. Jaeger P, Burckhardt P, Wauters JP, Trechsel U, Bonjour JP: Evidence for a particularly severe secondary hyperparathyroidism in analgesic abuse nephropathy. Am J Nephrol 5: 342, 1985

    PubMed  CAS  Google Scholar 

  167. Fröhling PT, Kokot F, Verter K, Kaschube I, Lindenau K: Influence of vitamin D or its metabolites on the rate of progression of chronic renal failure. Contr Nephrol 53: 64, 1986

    Google Scholar 

  168. Pietrek J, Kokot F, Kuska J: Effects of 1-a-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal failure. Int Urol Nephrol 10:153, 1978

    PubMed  CAS  Google Scholar 

  169. Fröhling PT, Schmicker P, Kokot F, Vetter K, Kaschube I, Götz K-H, Jacopian M, Lindenau K: Influence of phosphate restriction, ketoacids and vitamin D on the progression of renal failure. Proc Eur Dial Transplant Assoc Eur Ren Assoc 21: 561, 1984

    Google Scholar 

  170. Fröhling PT, Kokot F, Vetter K, Hohmann WD, Werber G, Grossmann T, Schmicker P, Lindenau K: Treatment of osteodystrophy in advanced renal failure during predialysis time. Contrib Nephrol 37: 62, 1984

    PubMed  Google Scholar 

  171. Fröhling PT, Schmidt-Gayk H, Kokot F, Vetter K, Mayer E, Lindenau K: Influence of vitamin D and keto acids /KA/ on l,25/OH/2D levels in chronic renal failure. In: Vitamin D, Biochemical and Clinical Update, edited by Norman AW, Schaefer K, Grigoleit H-G, v. Herrath D, Berlin, Walter de Gruyter, 1985, p 952

    Google Scholar 

  172. Takamoto S, Onishi T, Mirimoto S, Imanaka S, Tsuchiya H, Seino Y, Yokokawa T, Lida N, Kumahara Y: Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: effect of aluminium hydroxide administration. Nephron 40: 286, 1985

    PubMed  CAS  Google Scholar 

  173. McGonigle RJS, Fowler MB, Timmis AB, Weston MJ, Parsons V: Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron 36: 94, 1984

    PubMed  CAS  Google Scholar 

  174. Fröhling PT, Kokot F, Schmicker R, Kaschube I, Lindenau K, Vetter K: Influence of ketoacids on serum parathyroid hormone levels in patients with chronic renal failure. Clin Nephrol 20: 212, 1983

    PubMed  Google Scholar 

  175. Cunningham J, Segre GV, Slatopolsky E, Avioli LV: Effect of histamine H2-receptor blockade on parathyroid status in normal and uraemic man. Nephron 38: 17, 1984

    PubMed  CAS  Google Scholar 

  176. Kokot F, Kuska J, Sledzinski Z, Bialas B, Luciak M: Parathormon, Kalzitonin, 25-Hydroxykalziferol und Knochenhistologie bei Patienten mit chronischer Niereninsuffizienz. (Parathormone, calcitonin, 25-hydroxycalciferol and bone histology in patients with chronic renal insufficiency.) Z Gesamte Inn Med 34: 665, 1979

    PubMed  CAS  Google Scholar 

  177. Malluche HH, Taugere MC, Ritz E, Caillens G, Wildberger D: Endogenous calcitonin does not protect against hyperparathyroid bone disease in renal failure. Miner Electrolyte Metab 12: 113, 1986

    PubMed  CAS  Google Scholar 

  178. Zazgornik J, Kokot F, Pietrek J, Schmidt P, Kopsa H: Osteopathie, Parathormon- und 25-Hydroxycholekalziferol-Konzentrationen im Serum bei chronisch dialysierten Patienten. (Osteopathy, serum parathormone and 25-hydroxycholecalciferol levels in patients on long term hemodialysis.) Wien Klin Wochenschr 90: 496, 1978

    PubMed  CAS  Google Scholar 

  179. Zazgornik J, Kokot F, Fürst K, Schmidt P, Pietrek J, Czembirek H, Kopsa H, Balcke P, Paietta E: Roentgenologic soft tissue and bone changes, parathyroid hormone, 25-hydroxycholecalciferol, calcium-phosphorus concentrations in serum in dialyzed and renal transplant patients. Dial Transplant 8: 389, 1979

    Google Scholar 

  180. Kokot F, Kuska J, Pietrek J: Das Verhalten der Parathormonsekretion bei hämodialysierten Patienten mit chronischer Niereninsuffizienz. (Behavior of parathyroid hormone secretion in hemodialysis patients with chronic renal failure.) Z Gesamte Inn Med 30: 443, 1975

    PubMed  CAS  Google Scholar 

  181. Schaefer K, v. Herrath D Pauls A Hufler M: New insight into hemofiltration. Semin Nephrol 6: 161, 1986

    PubMed  CAS  Google Scholar 

  182. Zucchelli P, Catizone L, Casanova S, Fusaroli M, Fabbri L, Ferrari G: Renal osteodystrophy in CAPD patients. Miner Electrolyte Metab 10: 326, 1984

    PubMed  CAS  Google Scholar 

  183. Delmez JA, Fallon MD, Bergfeld MA, Gearing BK, Dougan CS, Teitelbaum SL: Continuous ambulatory peritoneal dialysis and bone. Kidney Int 30: 379, 1986

    PubMed  CAS  Google Scholar 

  184. Kokot F, Zazgornik J, Pietrek J, Schmidt P, Fürst K, Czembirek H, Kopsa H: Parathormon- und 25-Hydroxycholekal- ziferol-Konzentrationen im Serum nierentransplantierter Patienten und ihr röntgenologisches Korrelation. (Parathormone and 25-hydroxycholecalciferol concentrations in the serum of renal transplant patients and their roentgenologic correlation.) Z Gesamte Inn Med 33: 516, 1978

    PubMed  CAS  Google Scholar 

  185. Bonomini V, Campieri C, Feletti C, Orsoni G, Vangelista A: Hormonal abnormalities in renal transplantation. Contrib Nephrol 49: 70, 1985

    PubMed  CAS  Google Scholar 

  186. Fröhling PT, Kokot F, Cernacek P, Vetter K, Kuska J, Spustova V, Kaschube I, Dziurik R: Relation between middle molecules and parathyroid hormone in patients with chronic renal failure. Miner Electrolyte Metab 7: 48, 1982

    PubMed  Google Scholar 

  187. Martinez ME, Miguel JL, Gomez P, Selgas R, Salinas M, Gentil M, Mateos F, Montero JL, Sicilia LS: Plasma calcitonin concentration in patients treated with chronic dialysis: differences between hemodialysis and CAPD. Clin Nephrol 19: 250, 1983

    PubMed  CAS  Google Scholar 

  188. Kokot F, Kuska J, Mleczko Z, Szczechowska E, Pazera A: Über die Beziehung zwischen Gastrin- und Kalzitonin-Sekretion bei Kranken mit akuter und chronischer Niereninsuffizienz. (About the relationship between gastrin and calcitonin secretion in patients with acute and chronic renal insufficiency.) Dtsch Gesundh-Wesen 36: 429, 1981

    Google Scholar 

  189. Fuss M, Bergans A, Geurts J, Brauman H, Corvilain J: Effect of rapid variation of renal function on plasma calcitonin and parathyroid hormone in man. Acta Endocrinologica (Kbh) 92: 130, 1979

    PubMed  CAS  Google Scholar 

  190. Nielsen HE, Olsen KJ: Serum calcitonin after renal transplantation. Acta Med Scand 205: 619, 1979

    PubMed  CAS  Google Scholar 

  191. Kokot F, Nieszporek T: Influence of hemoperfusion on the concentrations of calcitonin, testosterone and Cortisol in blood plasma. Artif Organs 3: 332, 1979

    PubMed  CAS  Google Scholar 

  192. Ardaillou R, Sizonenko P, Meyner A, Valee G, Beaugas G: Metabolic clearance rate of radioiodinated human calcitonin in man. J Clin Invest 49: 2345, 1970

    PubMed  CAS  Google Scholar 

  193. Heynen G, Franchimont P: Human calcitonin and serum phosphate. Lancet 1: 267, 1974

    Google Scholar 

  194. Weidmann P, Maxwell MH, de Lima J, Hirsch D, Franklin SS: Control of aldosterone responsiveness in terminal renal failure. Kidney Int 7: 351, 1975

    PubMed  CAS  Google Scholar 

  195. Osten B, Wedler B: Untersuchungen zur Regulation und Funktion des Aldosterons unter besonderer Berücksichtigung der Nierenfunktion. (Investigation of the regulation and function of aldosterone with special attention to renal function.) Dissertationsschrift (Promotion B), Rostock, 1979

    Google Scholar 

  196. Schnurr E: Der Einfluss der Hämodialyse auf die Plasma-Aldosteron-Konzentration. Ein Beitrag zur Frage der Aldosteron-Regulation im Stadium der terminalen Niereninsuffizienz. (The influence of hemodialysis on plasma aldosterone concentration. A study concerning aldosterone regulation in states of renal insufficiency.) Habilitationsschrift, Düsseldorf, 1976

    Google Scholar 

  197. Vetter W, Haruba K, Armbruster H, Beckerhoff R, Nussberger J, Furrer J, Fontana A, Siegenthaler W: Control of plasma aldosterone during hemodialysis patients with terminal renal failure. Nephron 18: 114, 1977

    PubMed  CAS  Google Scholar 

  198. Wedler B, Osten B, Schmidt R, Klinkmann H: Zum Verhalten des Serumaldosterons unter de Hämodialyse bei Patienten mit chronischer Niereninsuffizienz. (The behavior of serum aldosterone in patients with renal insufficiency undergoing hemodialysis.) Dtsch Gesundh-Wesen 32: 1912, 1977

    Google Scholar 

  199. Hene RJ, RoomansHA, BoerP, RoosJC, Dorhout Mees EJ: Relation between plasma aldosterone concentration and renal handling of sodium and potassium, in particular in patients with chronic renal failure. Nephron 37: 94, 1984

    PubMed  CAS  Google Scholar 

  200. Rissmann K: Untersuchungen zur Aldosteronsekretion bei Patienten mit terminaler chronischer Niereninsuffizienz während der Hämodialysebehandlung. (Investigation of aldosterone secretion in patients with terminal renal failure undergoing hemodialysis treatment.) Dissertation, Aachen, 1979

    Google Scholar 

  201. Dordevi V, Kosti S, Stefanovi V: Study of plasma aldosterone in patients on chronic hemodialysis. Acta Med Jugosl 40: 49, 1986

    Google Scholar 

  202. Campese VM, Iseki K, Massry SG: Plasma catecholamines and vascular reactivity in uremic and dialysis patients. Contrib Nephrol 41: 90, 1984

    PubMed  CAS  Google Scholar 

  203. Campese VM, Massry SG: Plasma catecholamines and vascular reactivity in acute and chronic renal failure. Contrib Nephrotic 128, 1985

    Google Scholar 

  204. Cuche J-L, Prinseau J, Selz F, Rüget G, Baglin A: Plasma free, sulfo- and glucuro-conjugated catecholamines in uremic patients. Kidney Int 30: 566, 1986

    PubMed  CAS  Google Scholar 

  205. Lake CR, Ziegler MG, Coleman MD, Kopin IJ: Plasma levels of norepinephrine and dopamine-β-hydroxylase in CRF patients treated by dialysis. Cardiol Med 9: 1099, 1979

    Google Scholar 

  206. McGrath BP, Ledingham JGG, Benedict CR: Catecholamines in peripheral venous plasma in patients on chronic haemodialysis. Clin Sci Mol Med 55: 89, 1978

    PubMed  CAS  Google Scholar 

  207. Brecht HM, Ernst W, Koch KM: Plasma noradrenaline levels in regular haemodialysis patients. Proc Eur Dial Transplant Assoc 12: 281, 1975

    Google Scholar 

  208. Zuccala A, Santoro A, Gaggi R, Chiarini C, Degli Eposti E, Sturani A, Zucchelli P: Relationship between plasma noradrenaline and blood pressure in uremia. Contrib Nephrol 49: 134, 1985

    PubMed  CAS  Google Scholar 

  209. deFronzo RA, Andres R, Edgar P, Walker WG: Carbohydrate metabolism in uremia. A review. Medicine 52: 469, 1973

    PubMed  CAS  Google Scholar 

  210. Kokot F, Kuska J: Das Verhalten der Insulinsekretion bei chronischer Niereninsuffizienz. (Behavior of insulin secretion in chronic renal insufficiency.) Z Gesamte Inn Med 28: 351, 1973

    PubMed  CAS  Google Scholar 

  211. Wnuk R, Kokot F, Mleczko Z: Endocrine pancreatic function in patients with acute and chronic renal failure. Pol Arch Med Wewn 70: 111, 1983

    PubMed  CAS  Google Scholar 

  212. Spitz IM, Rubenstein AN, Bersohn I, Abrahams C, Lowy C: Carbohydrate metabolism in renal disease. Q J Med 39: 201, 1970

    PubMed  CAS  Google Scholar 

  213. Milutinovic S, Breyer D, Molnar V, Stefovic A, Jankovic N, Skrabalo Z, Rocic B: Changes in insulin binding during hemodialysis in uremic patients. Nephron 41: 307, 1985

    PubMed  CAS  Google Scholar 

  214. Schmitz O: Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes 34: 1159, 1985

    Google Scholar 

  215. Brech WJ: Urämische Glukoseintoleranz — Diabetes mellitus. (Uremic glucose intolerance — diabetes mellitus.) In: Blutreinigungsverfahren — Technik und Klinik (Blood Purification Treatment — Technical and Clinical Aspects), edited by Franz HE, Stuttgart, Hrsg Thieme, 1981, 0 167

    Google Scholar 

  216. Fisch HP: Funktionsstörungen endokriner Drüsen bei chronischer Niereninsuffizienz. (Endocrine gland functional disorders in chronic renal insufficiency.) Med Klin 74:1363, 1979

    PubMed  CAS  Google Scholar 

  217. Taylor R, Heaton A, Hetherington CS, Alberti KG: Adipocyte insulin binding and insulin action in chronic renal failure before and during continuous ambulatory peritoneal dialysis. Metabolism 35: 430, 1986

    PubMed  CAS  Google Scholar 

  218. Davidson MB, Fister MB, Dabir-Vaziri N, Schaffer M: Effect of protein intake and dialysis on the abnormal growth hormone, glucose and insulin homeostasis in uremia. Metabolism 25: 455, 1976

    PubMed  CAS  Google Scholar 

  219. Armstrong VW, Buschmann U, Ebert R, Fuchs C, Rieger J, Scheler F: Biochemical investigations of CAPD: plasma levels of trace elements and amino acids, and impaired glucose tolerance during the course of treatment. Int J Artif Organs 3: 327, 1980

    Google Scholar 

  220. Gahl GM: Medical management of continuous ambulatory peritoneal dialysis. In: Continuous Ambulatory Peritoneal Dialysis, edited by Legrain M, Excerpta Medica, Amsterdam, 1980, p 181

    Google Scholar 

  221. Armstrong VW, Creutzfeldt W, Ebert R, Fuchs C, Hilgers R, Scheler F: Effect of dialysate glucose on plasma glucose and glucoregulatory hormones in CAPD patients. Nephron 39: 141, 1985

    PubMed  CAS  Google Scholar 

  222. Bilbrey EL, Faloona GR, Withe MA, Knöchel JP: Hyperglucagonemia of renal failure. J Clin Invest 53: 841, 1974

    PubMed  CAS  Google Scholar 

  223. Sherwin RS, Basti C, Finkelstein FO, Fisher M, Black H, Hendler R, Felig P: Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. J Clin Invest 57: 722, 1976

    PubMed  CAS  Google Scholar 

  224. Punz KK, Yeung CK, Yeung RTT: Effects of propranolol and metoprolol on glucose, cyclic AMP and insulin responses during pharmacologic hyperglucagonemia in hemodialysis patients. Nephron 39: 175, 1985

    Google Scholar 

  225. Duckworth WC, Heinemann M, Kemp I: Insulin and glucagon degradation by kidney. Clin Res 23: 318, 1975

    Google Scholar 

  226. El Ghonaimy E, Barsoum R, Soliman M, El Fikky A, Rashwan S, El Rouby O, Haddad S, El Khashab O, Abou Zeid M, Hassaballah N, Hassaballah A: Serum gastrin in chronic renal failure: morphological and physiological correlations. Nephron 39: 86, 1985

    PubMed  Google Scholar 

  227. Muto S, Murayama N, Asano Y, Hosonda S, Miyata M: Hypergastrinemia and achlorhydria in chronic renal failure. Nephron 40: 143, 1985

    PubMed  CAS  Google Scholar 

  228. Kokot F, Kröl Z, Mleczko Z, Pazera A, Szczechowska E: Der Einfluss von Cimethidin auf den Serumgastrinspiegel bei chronischem Nierenversagen. (The effect of Cimetidine on serum gastrin levels in chronic renal failure.) Dtsch Gesundh-Wesen 36: 471, 1981

    Google Scholar 

  229. Kuska J, Kokot F, Gerlach J: Gastrinaemia after intravenous calcium load in patients with acute and chronic renal failure. Pol Arch Med Wewn 63: 149, 1980

    PubMed  CAS  Google Scholar 

  230. Korman MG, Laver MC, Hansky J: Hypergastrinemia in chronic renal failure. Br Med J 1: 209, 1972

    Google Scholar 

  231. Owyang C, Miller LJ, Di Mango EP, Brennan LA, Go VLW: Gastrointestinal hormone profile in renal insufficiency. Mayo Clin Proc 63: 769, 1979

    Google Scholar 

  232. Sirinek KR, O’Dorlsio TM, Gaskill HV, Levine BA: Chronic renal failure: effect of hemodialysis on gastrointestinal hormones. Am J Surg 148: 732, 1984

    PubMed  CAS  Google Scholar 

  233. Gold CH, Morley JE, Viljoen M, Tim LO, Fomseca M, Kalk WJ: Gastric acid secretion and serum gastrin levels in patients with chronic renal failure on regular hemodialysis. Nephron 25: 92, 1980

    PubMed  CAS  Google Scholar 

  234. Grace SG, Davidson WD, State D: Renal mechanism for removal of gastrin from the circulation. Surg Forum 25: 323, 1974

    PubMed  CAS  Google Scholar 

  235. Balman RM, Cooper WS, Garner SC, Munson PL, Wells SAJ: Stimulation of gastrin secretion in the pig by parathyroid hormone and its inhibition by thyrocalcitonin. Endocrinology 100: 1014, 1977

    Google Scholar 

  236. Taylor IL, Sells RA, Mc Connell RB, Dockray GO: Serum gastrin in patients with chronic renal failure. Gut 21: 1062, 1980

    PubMed  CAS  Google Scholar 

  237. Sullivan SN, Tustanoff E, Slaughter DN: Hypergastrinemia and gastric acid hypersecretion in uremia. Clin Nephrol 5: 25, 1976

    PubMed  CAS  Google Scholar 

  238. Wesdorp RIC, Falcao HA, Banks PB, Martino J, Fischer JE: Gastrin and gastric acid secretion in renal failure. Am J Surg 141: 334, 1981

    PubMed  CAS  Google Scholar 

  239. Nielsen HE, Christensen CK, Brandsborg M, Brandsborg O: The effect of renal transplantation on basal serum gastrin concentration. Acta Med Scand 207: 85, 1980

    PubMed  CAS  Google Scholar 

  240. Balcke P, Pointner H: Serumgastrin nach Nierentransplantation. (Serum gastrin after renal transplantation.) Wien Klin Wochenschr 92: 86, 1980

    PubMed  CAS  Google Scholar 

  241. Zukowska-Szczechowska E, Kokot F, Grzeszczak W: Gastrinaemia in renal graft recipients treated by cyclosporine A or azathioprine with prednisone Acta Med Pol (in press)

    Google Scholar 

  242. Lauritzen JB, Lauritzen KB, Olsen ME, Timmerman I: Gastric inhibitory polypeptide (GIP) and insulin release in response to oral and intravenous glucose in uremic patients. Metabolism 9:1096, 1982

    Google Scholar 

  243. Grekas DM, Raptis S, Tourkantonis AA: Plasma secretin, pancreozymin and somatostatin-like hormone in chronic renal failure patients. Uremia Invest 8: 117, 1984–1985

    CAS  Google Scholar 

  244. Lugari R, David S, Dall’Augine P, Nicolotti V, Parmeggiani A, Gnudi A, Luciani A, Toscani S, Zandomeneghi R: Human pancreatic polypeptide and somatostatin in chronic renal failure. Proc Eur Dial Transplant Assoc Eur Ren Assoc 21: 614, 1985

    PubMed  CAS  Google Scholar 

  245. Boden G, Master RW, Owen OE, Rudnik MR: Human pancreatic polypeptide in chronic renal failure and cirrhosis of the liver: role of kidneys and liver in pancreatic polypeptide metabolism. J Clin Endocrinol Metab 51: 573, 1980

    PubMed  CAS  Google Scholar 

  246. Henriksen JH, Staun-Olsen P, Borg Mogensen N, Fahrenkrug J: Circulating endogenous vasoactive intestinal polypeptide (VIP) in patients with uraemia and liver cirrhosis. Eur J Clin Invest 16: 211, 1986

    PubMed  CAS  Google Scholar 

  247. Needleman P, Adams SP, Cole BR, Currie MG, Geller DM, Michener ML, Saper CB, Schwartz D, Standaert DG: Atriopeptins as cardiac hormones. Hypertension 7: 469, 1985

    PubMed  CAS  Google Scholar 

  248. Needleman P, Greenwald JE: Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood pressure homeostatis. N Engl J Med 314: 828, 1986

    PubMed  CAS  Google Scholar 

  249. Eisenhauer T, Talartschik ?, Scheler F: Detection of fluid overload by plasma concentration of human atrial natriuretic peptide (h-ANP) in patients with renal failure. Klin Wochenschr 64 (Suppl VI): 68, 1986

    PubMed  Google Scholar 

  250. Rascher W, Tulassy T, Lang RE: Atrial natriuretic peptide in plasma of volume overloaded children with chronic renal failure. Lancet 2: 303, 1985

    PubMed  CAS  Google Scholar 

  251. Hartter E, Pacher R, Frass M, Woloszczuk W, Leithner C: Plasma levels of atrial natriuretic peptide (ANP) in volume expanded patients: response to fluid removal by continuous pump driven hemofiltration. Klin Wochenschr 64 (Suppl VI): 112, 1986

    PubMed  Google Scholar 

  252. Luft FC, Sterzel RB, Lang RE, Trabold EM, Veelken R, Ruskoaho H, Gao Y, Ganten D, Unger T: Atrial natriuretic factor determinations and chronic sodium homeostasis. Kidney Int 29:1004, 1986

    PubMed  CAS  Google Scholar 

  253. Smith S, Anderson S, Ballermann BJ, Brenner BM: Role of atrial natriuretic polypeptide in adaptation of sodium excretion with reduced renal mass. J Clin Invest 77: 1395, 1986

    PubMed  CAS  Google Scholar 

  254. De Wardener HE, Clarkson EM: Concept of natriuretic hormone. Physiol Rev 65: 658, 1985

    PubMed  Google Scholar 

  255. Buckalew VM, Gruber KA: Natriuretic hormone. Annu Rev Physiol 46: 343, 1984

    PubMed  CAS  Google Scholar 

  256. Kelly RA, O’Hara DS, Mitch WE, Steinman TI, Goldszer RC, Solomon HS, Smith TW: Endogenous digitalis-like factors in hypertension and chronic renal insufficiency. Kidney Int 30: 723, 1986

    PubMed  CAS  Google Scholar 

  257. Greenway DC, Nanji AA: Digoxin-like immunoreactive substance in renal failure: a reappraisal. Nephron 44: 108, 1986

    PubMed  CAS  Google Scholar 

  258. Kramer HJ, Pennig J, Klingmüller D, Kipnowski J, Glänzer K, Düring R: Digoxin-like immunoreactivity substance(s) in the serum of patients with chronic uremia. Nephron 40: 297, 1985

    PubMed  CAS  Google Scholar 

  259. Graves SW, Brown B, Waldes R: An endogenous digoxin-like substance in patients with renal impairment. Ann Intern Med 99: 604, 1983

    PubMed  CAS  Google Scholar 

  260. Gilkdes JJH, Eady RAJ, Rees LH, Monro DD, Moorhead JF: Plasma immunoreactive melantropic hormones in patients on maintenance hemodialysis. Br Med J 1: 656, 1975

    Google Scholar 

  261. Kuhn JM, Luton JP, Bricaire H: ACTH, β-endorphine, lipotropines: Études physiophahologiques chez l’homme. (ACTH, ß endorphin, lipotropins: Pathophysiological studies in man.) Ann Med Interne 133: 148, 1982

    CAS  Google Scholar 

  262. Aronin N, Liotta AA, Shickmanter B, Schyssler GC, Krieger GT: Impaired clearance of ß-lipotropin in uremia. J Clin Endocrinol Metab 53: 797, 1981

    PubMed  CAS  Google Scholar 

  263. Smith R, Grossman A, Gaillard R, Clement Jones V, Ratter S, Mallinson J, Lowry PJ, Besser GM, Rees LH: Studies on circulating MET-enkephalin and ß-endorphin: normal subjects and patients with renal and adrenal disease. Clin Endocrinol 15: 291, 1981

    CAS  Google Scholar 

  264. Zoccali C, Ciccarelli M, Mallamaci F, Maggiore Q: [MET]-enkephalin and [Leu]-enkephalin plasma levels in chronic renal failure Nephrol Dial Transplant 1: 219, 1987

    PubMed  CAS  Google Scholar 

  265. Zoccali C, Ciccarelli M, Mallamaci F, Maggiore Q: Effect of naloxone on the defective autonomic control of heart rate in uraemic patients. Clin Sci 69: 81, 1985

    PubMed  CAS  Google Scholar 

  266. Amico JA, Doll RB Jr, Finn FM, Ervin MG, Leake RD, Fisher DA, Ribonson AG: High pressure liquid chromatographic separation of an oxytocin/arginine vasotocin-like peptide from the plasma of patients with chronic renal failure. J Clin Endocrinol Metab 60: 644, 1985

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Franciszek Kokot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrzej Więcek
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Nephrology Division, F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA

    John F. Maher M.D., FACP (Professor of Medicine, Director) (Professor of Medicine, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers

About this chapter

Cite this chapter

Kokot, F., Więcek, A. (1989). Endocrine Changes in Chronic Dialysis Patients. In: Maher, J.F. (eds) Replacement of Renal Function by Dialysis. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-1087-4_45

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-1087-4_45

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6979-3

  • Online ISBN: 978-94-009-1087-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation